Urinary beta-glucuronidase in screening and followup of primary urinary tract malignancy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 7658533.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The usefulness of urinary beta-glucuronidase in screening and followup of urinary tract malignancy was tested. The activity and concentration of urinary beta-glucuronidase were determined in 80 healthy subjects, 113 urology patients with no cancer, and 60 with transitional cell and 23 with renal cell carcinoma. Patients with cancer were followed for 3 to 33 weeks. The enzyme activity and concentration were significantly greater in the cancer group, including residual tumor or recurrence after therapy, than in the controls with excellent discrimination. Urinary beta-glucuronidase was indeed useful in screening and followup of urinary tract malignancy.
Medical subject headings
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Glucuronidase
- Kidney Neoplasms